MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer Journal Article
| Authors: | Von Boehmer, L.; Keller, L.; Mortezavi, A.; Provenzano, M.; Sais, G.; Hermanns, T.; Sulser, T.; Jungbluth, A. A.; Old, L. J.; Kristiansen, G.; Van Den Broek, M.; Moch, H.; Knuth, A.; Wild, P. J. |
| Article Title: | MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer |
| Abstract: | The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of CT antigen expression has not yet been reported in prostate cancer. MAGE-C2/CT-10 is a novel CT antigen. The objective of this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. 348 prostate carcinomas from consecutive radical prostatectomies, 29 castration-refractory prostate cancer, 46 metastases, and 45 benign hyperplasias were immunohistochemically analyzed for MAGE-C2/CT10 expression using tissue microarrays. Nuclear MAGE-C2/CT10 expression was identified in only 3.3% primary prostate carcinomas. MAGE-C2/CT10 protein expression was significantly more frequent in metastatic (16.3% positivity) and castration-resistant prostate cancer (17% positivity; p<0.001). Nuclear MAGE-C2/CT10 expression was identified as predictor of biochemical recurrence after radical prostatectomy (p = 0.015), which was independent of preoperative PSA, Gleason score, tumor stage, and surgical margin status in multivariate analysis (p<0.05). MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. Further, the results suggest MAGE-C2/CT10 as a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer. © 2011 von Boehmer et al. |
| Keywords: | immunohistochemistry; adult; cancer survival; controlled study; human tissue; protein expression; aged; unclassified drug; major clinical study; cancer recurrence; disease free survival; cancer staging; prostate specific antigen; metastasis; prostate cancer; gleason score; prostatectomy; melanoma antigen; prostate hypertrophy; cell nucleus; tissue microarray; predictive value; castration resistant prostate cancer; recurrence free survival; melanoma antigen c2 |
| Journal Title: | PLoS ONE |
| Volume: | 6 |
| Issue: | 7 |
| ISSN: | 1932-6203 |
| Publisher: | Public Library of Science |
| Date Published: | 2011-01-01 |
| Start Page: | e21366 |
| Language: | English |
| DOI: | 10.1371/journal.pone.0021366 |
| PROVIDER: | scopus |
| PMCID: | PMC3130772 |
| PUBMED: | 21754986 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 17 August 2011" - "Art. No.: e21366" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work